466 related articles for article (PubMed ID: 29948928)
1. Pediatric Cancer Immunotherapy: Opportunities and Challenges.
Wedekind MF; Denton NL; Chen CY; Cripe TP
Paediatr Drugs; 2018 Oct; 20(5):395-408. PubMed ID: 29948928
[TBL] [Abstract][Full Text] [Related]
2. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
3. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers.
Majzner RG; Heitzeneder S; Mackall CL
Cancer Cell; 2017 Apr; 31(4):476-485. PubMed ID: 28366678
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapy strategies for hepatobiliary cancers.
DeLeon TT; Zhou Y; Nagalo BM; Yokoda RT; Ahn DH; Ramanathan RK; Salomao MA; Aqel BA; Mahipal A; Bekaii-Saab TS; Borad MJ
Immunotherapy; 2018 Sep; 10(12):1077-1091. PubMed ID: 30185133
[TBL] [Abstract][Full Text] [Related]
6. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
8. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of immunotherapy.
Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
[TBL] [Abstract][Full Text] [Related]
11. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Maude SL
Clin Adv Hematol Oncol; 2018 Oct; 16(10):664-666. PubMed ID: 30543595
[No Abstract] [Full Text] [Related]
12. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
13. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
14. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
15. The Promise and Challenges of CAR-T Gene Therapy.
Kuehn BM
JAMA; 2017 Dec; 318(22):2167-2169. PubMed ID: 29167891
[No Abstract] [Full Text] [Related]
16. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
17. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG
J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
Joshi M; Pal SK; Drabick JJ
Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
[TBL] [Abstract][Full Text] [Related]
19. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Lohmueller J; Finn OJ
Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974
[TBL] [Abstract][Full Text] [Related]
20. The swinging pendulum of cancer immunotherapy personalization.
Abraham TS; Snook AE
Per Med; 2017 May; 14(3):259-270. PubMed ID: 29767586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]